Isto Biologics (“Isto”), a biologics company dedicated to advancing bone healing, announces the acquisition of NovaBone Products LLC (“NovaBone”), a developer and manufacturer of synthetic bone graft products, from Halma plc. Supported by Keensight Capital (“Keensight”), one of the leading private equity managers dedicated to pan-European Growth Buyout[1] investments, the acquisition adds a differentiated portfolio of bioactive glass technologies and expands Isto’s ability to support surgeons with a broader range of bone graft options. Founded in 2002 and headquartered in Alachua, Florida, NovaBone develops and manufactures synthetic bone grafts based on its proprietary bioactive glass technology, which are sold in more than 40 countries worldwide.
Read the full article: Isto Biologics Strengthens Its Bone Graft Substitutes Platform with the Acquisition of Novabone //
Source: https://keensight.com/isto-biologics-strengthens-its-bone-graft-substitutes-platform-with-the-acquisition-of-novabone/